The use of very low concentrations of high sensitivity troponin T to rule out acute myocardial infarction using a single blood test
Abstract Background
Recent single center and retrospective studies suggest that acute myocardial infarction (AMI) could be immediately excluded without serial sampling in patients with initial high sensitivity troponin T (hs-cTnT) levels below the limit of detection (LoD) of the assay and no ECG ischemia.
Objective
We aimed to determine the external validity of those findings in a multi-center study at 12 sites in 9
countries.
Methods
TRAPID-AMI was a prospective diagnostic cohort study including patients with suspected cardiac chest pain within 6h of peak symptoms. Blood drawn on arrival was centrally tested for hs-cTnT (Roche, 99 th percentile 14ng/L, LoD 5ng/L). All patients underwent serial troponin sampling over 4-14h. The primary outcome, prevalent AMI, was adjudicated based on sensitive troponin I (Siemens Ultra) levels. Major adverse cardiac events (MACE) including AMI, death or rehospitalisation for acute coronary syndrome with coronary revascularization were determined after 30 days.
Results
We included 1,282 patients, of whom 213 (16.6%) had AMI and 231 (18.0%) developed MACE. Of 560 (43.7%) patients with initial hs-cTnT levels below the LoD, 4 (0.7%) had AMI. In total, 471 (36.7%) patients had both initial hs-cTnT levels below the LoD and no ECG ischemia. These patients had a 0.4% (n=2) probability of AMI, giving 99.1% (95% CI 96.7-99.9%) sensitivity and 99.6% (95% CI 
Background
High sensitivity cardiac troponin assays enable the detection of cardiac troponin in at least 50% of apparently healthy individuals with improved precision at the 99 th percentile of an apparently healthy reference population. 1 In addition to having greater analytical sensitivity, which permits the detection of lower troponin concentrations, these assays have also been shown to have higher diagnostic sensitivity when used in patients with suspected acute coronary syndromes presenting to an Emergency Department (ED). 2 However, while this does mean that a greater proportion of patients who have an acute myocardial infarction (AMI) can be positively identified at the time of initial presentation, serial sampling remains necessary before the diagnosis of AMI can be safely excluded. 3 This causes an anxious wait for patients, contributes to the growing problem of ED overcrowding, and incurs a financial cost. A rule out strategy that could rule out AMI in a proportion of patients using a single blood test would help to address these problems.
Although high sensitivity assays permit detection of troponin concentrations below the 99 th percentile, such low levels are within the normal range and are not currently used to guide clinical care. However, there is growing evidence to suggest that the use of cut-offs below the 99 th percentile could enable AMI to be immediately excluded in a proportion of patients. For the high sensitivity troponin T (hs-cTnT) assay (Roche Diagnostics Elecsys®), which has a 99 th percentile of 14ng/L, results may be reported as low as the limit of blank (LoB), which is 3ng/L. The LoB is defined as the mean observed result plus 1.645 standard deviations when testing a sample containing no analyte. Meanwhile, the limit of detection (LoD; 5ng/L) is defined as the LoB plus 1.645 standard deviations of results obtained from a low concentration sample, and is therefore the lowest troponin concentration that might reasonably be distinguished from the LoB. 4 A recent meta-analysis combining the findings of 23 studies evaluating hs-cTnT cut-offs set at either the LoB or the LoD showed a pooled sensitivity of 97.4% (95% CI 94.9 -98.7%). 5 Some may consider that missing 2.6% of AMIs is unacceptable. However, a retrospective study of over 15,000 patients has also shown that negative predictive value (NPV) may be further improved if AMI is only 'ruled out' in patients who have no ECG ischemia. 6 Indeed a more recent single center prospective study of 463 patients reported that 'ruling out' AMI in patients with initial hs-cTnT concentrations <5ng/L and no ECG ischemia had a sensitivity of 100% (95% CI 95.4 -100.0%).
7
Given the important prognostic and medicolegal implications of ruling out a diagnosis of AMI at the time of arrival in the ED, it is imperative that promising early findings are prospectively and robustly validated in large, heterogeneous cohorts before clinical implementation. Our objective was therefore to determine whether hs-cTnT concentrations measured at the time of arrival in the ED can safely exclude AMI using cut-offs below the 99 th percentile, either when used alone or in combination with ECG findings.
Methods

Design and setting
We conducted a secondary analysis of data from the TRAPID-AMI (High sensitivity cardiac troponin T assay for RAPID rule out of Acute Myocardial Infarction) study, a multi-center prospective diagnostic cohort study conducted at 12 sites in 9 countries worldwide (see Appendix). 8 Patients aged over 18 years who presented to the ED with new onset chest pain or other symptoms suggestive of an acute coronary syndrome that had peaked within 6 hours of presentation were eligible to participate. We excluded patients with acute trauma; those who had received thrombolytic or other revascularization therapy in the pre-hospital setting; patients who required defibrillation or cardioversion pre-hospital or in the ED; patients who had undergone cardiac surgery within 1 month of presentation; patients hospitalized for AMI in the previous 3 weeks; those with end-stage renal disease requiring dialysis; patients who had previously been included in the study; and pregnant or 
Data collection and processing
Baseline clinical data were collected at the time of initial presentation using a custom-designed case report form. 
Outcomes
The primary outcome, for the purpose of the present analysis, was a diagnosis of AMI (prevalent at the time of initial admission). The diagnosis was adjudicated by a central adjudication committee consisting of two independent cardiologists, with reference to a third cardiologist in the event of disagreement. In accordance with the Third Universal definition, patients were considered to fulfil the diagnosis of AMI if they developed a rise and/or fall of troponin with at least one value above the 99 th percentile of a healthy reference population in the appropriate clinical context. 3 The adjudication committee had access to all relevant clinical records including the patient history, physical examination, ECG, imaging investigations and s-cTnI concentrations; but the committee was blinded to hs-cTnT concentrations as well as routine troponin measurements made during the course of clinical care.
The occurrence of major adverse cardiac events (MACE) within 30 days was a secondary outcome.
MACE included death (all cause), AMI (both prevalent and incident within the 30-day follow-up period) and re-hospitalization for an acute coronary syndrome. Revascularization included both percutaneous coronary intervention and coronary artery bypass grafting. This outcome had been defined to best reflect the incidence of recurrent ischemia. In-hospital revascularization was not included as our group felt that this outcome was more subjective, influenced by local practices and not necessarily ischemia driven. However, we have reported the incidence of in-hospital revascularization separately. To avoid the possibility that we would overestimate diagnostic accuracy by adjudicating the diagnosis of AMI using the s-cTnI assay, we ran a sensitivity analysis. In this analysis we evaluated the diagnostic accuracy of hs-cTnT cut-offs below the 99 th percentile for predicting a peak hs-cTnT level above the 99 th percentile (>14ng/L) on serial sampling.
Sensitivity analysis
Statistical analysis
Categorical data were summarized with frequencies and percentages and continuous data were summarized by the mean and standard deviation (for normal data) or median and interquartile range (for non-normal data). Conformity to the normal distribution was determined by the Kolmogorov-Smirnov test, with a two-tailed alpha of <0.05 denoting statistical significance. Sample size was determined based on the primary analysis for this study (to validate a 1-hour rule in and rule out algorithm) but we calculated a priori that a sample of 1,233 patients would have 90% power to determine that the negative predictive value of the 1-hour rule out algorithm is no lower than 99.5% with an alpha of 0.05. We aimed to enrol approximately 1,400 patients in total to account for dropouts.
Results
Between August 2011 and June 2013 we enrolled 1,458 patients with suspected acute coronary syndromes, of whom 1,282 had sufficient data for inclusion in this analysis. In total, 213 (16.6%) evaluable patients were diagnosed with AMI on their initial admission (prevalent AMI). Follow up at Further details of the 4 patients with initial hs-cTnT levels below LoD but who were given an adjudicated diagnosis of AMI are shown in Table 3 . The incidence of MACE and other secondary outcomes within 30 days among patients with initial hs-cTnT levels below each of the cut-offs studied are shown in Table 4 .
The diagnostic performance at alternative cut-offs below the 99 th percentile and diagnostic performance stratified by age, gender and the time from peak symptoms to blood draw are reported in detail in the Appendix, (Supplementary Tables 2 to 8 ). There was a notable difference in diagnostic performance among older patients (Supplementary Tables 3 and 4) . Among patients aged <65 years, 55.2% (n=400) had an initial hs-cTnT <5ng/L and no ECG ischemia. In this younger subgroup, the sensitivity of this strategy was 100.0% (95% CI 95.9 -100.0%) for AMI and there was a 0.8% (95% CI 0.2 -2.2%) incidence of MACE at 30 days. However, only 12.7% (n=71) patients aged ≥65 years had an initial hs-cTnT <5ng/L and no ECG ischemia. In this older subgroup, sensitivity was 98.4% (95% CI 94.4 -99.8%) for AMI and the incidence of MACE was 4.3% (95% CI 0.9 -12.5%).
There were no differences in diagnostic performance between males and females although the proportion of females 'ruled out' by each strategy evaluated was greater (Supplementary Tables 5   and 6 ).
Sensitivity and NPV were also higher in patients who underwent blood testing at least 2 hours after peak symptoms. In this group, the LoD cut-off was 100% sensitive even without accounting for ECG ischemia. Among patients who underwent blood testing within 2 hours of peak symptoms, sensitivity at the LoD cut-off was 95.7% with NPV 98.7%. Sensitivity rose to 97.1% and NPV to 99.0% when ECG ischemia was taken into account (Supplementary Tables 7 and 8 ).
Sensitivity analysis
Full details of the diagnostic performance of the strategies evaluated for predicting a peak hs-cTnT level above the 99 th percentile on serial sampling are shown in the Appendix (Supplementary Table   9 ). In summary, our findings remained unchanged. A total of 437 (34.1%) patients had a peak hscTnT level above the 99 th percentile of the assay. Of the 350 patients with initial hs-cTnT levels below the LoB (<3ng/L) and no ECG ischemia, 1 (0.3%) subsequently developed a peak hs-cTnT level >14ng/L on serial sampling. Similarly, only 1 (0.2%) of the 471 patients with an initial hs-cTnT level below the LoD (<5ng/L) and no ECG ischemia developed a peak level >14ng/L. 
Discussion
These findings, from a large prospective cohort study undertaken at 12 sites across three continents internationally, show that patients who have hs-cTnT concentrations below the limit of detection of the assay (5ng/L) and who have no evidence of ECG ischemia at the time of first presentation in the ED could have the diagnosis of AMI immediately excluded without serial sampling. This strategy could obviate the need for serial sampling in over a third of patients with an extremely high negative predictive value (99.6%, 95% CI 98.5-100.0%) for AMI. This corroborates findings from previous similar research in smaller or retrospective studies. We also found that these patients had a low incidence of MACE within 30 days (1.3%, 95% CI 0.5 -2.8%), which could be lowered (to 1.1%, 95%
CI 0.3 -2.9%) by setting the 'rule out' cut off at the limit of blank (3ng/L) of the assay. It is important to note that our MACE outcome was designed to reflect incident ischemia and therefore did not include revascularizations that took place during the initial hospitalization. Accounting for these events, the total proportion of patients with hs-cTnT <5ng/L and no ECG ischemia who developed an adverse event within 30 days was 3.4% (95% CI 1.9-5.5%). While this outcome is subjective in nature and such events may not preclude safe discharge with outpatient follow up, these observational data do still suggest that clinical judgement is required prior to discharging patients and proceeding without further investigation.
Our subgroup analyses suggest that performance could be enhanced if use of the 'rule out' strategy is restricted to patients aged <65 years and/or to patients undergoing blood testing at least 2 hours after peak symptoms. Among patients aged <65 years, for example, over one half of the patients could have had AMI excluded immediately with no missed diagnoses of AMI and a very low (0.8%, 95% CI 0.2 -2.2%) incidence of MACE at 30 days. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This work builds on the findings of previous research into the accuracy of early 'rule out' strategies using hs-cTnT cut-offs below the 99 th percentile. Our findings agree with those in previous studies.
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In a meta-analysis of six studies including 4,623 patients, hs-cTnT concentrations below a 3-5ng/L threshold on arrival in the ED had a pooled sensitivity of 97.4% (95% CI 94.9-98.7%). 5 This is entirely consistent with our finding that sensitivity at the 5ng/L (LoD) threshold is 98.1% (95% 95.3-99.5%).
By also taking account of ECG findings (a standard of care in patients with suspected acute coronary syndromes), the sensitivity and negative predictive value are enhanced. Again, this is consistent with the findings of the large retrospective analysis by Bandstein et al, which suggested that the negative predictive value of an initial hs-cTnT concentration <5ng/L in patients without ECG ischemia is as high as 99.8% (95% CI 99.7 -99.9%). 6 That level of risk compares favorably with previous reports suggesting that, in practice, 2% of AMIs are missed in the ED. 9 Although we do not have the data to present a direct comparison, this also compares favorably with a 3-hour rule out strategy (sensitivity 98.2%) that has been advocated for use in clinical practice. 10, 11 Taken in conjunction with the findings of previous work, our multi-center, prospective study therefore provides compelling evidence that AMI may be excluded at the time of arrival in the ED in patients who have an initial hs-cTnT concentration below the limit of detection and no ECG ischemia, particularly in younger (<65 years) patients and those undergoing blood tests at least 2 hours after peak symptoms. This may represent one of the key advantages of using high sensitivity cardiac troponin assays in practice.
Patients with hs-cTnT levels above the LoD should not be considered to have the diagnosis 'ruled in' as levels below the 99 th percentile should still be considered as 'normal'. However, removing the need for serial sampling in over one third of patients will have substantial potential benefits for patients and health services alike. An even greater proportion of patients is likely to have the diagnosis of AMI 'ruled out' following serial sampling after 1 to 3 hours. 10, 12 The primary analysis Implementation would enable patients to benefit from earlier reassurance and may help to avoid hospital admission for patients in whom clinicians deem further investigation is unnecessary one the diagnosis of AMI has been excluded. Health services stand to benefit by reducing ED overcrowding, which is associated with an increase in patient mortality, 13 and by reducing the economic costs associated with unnecessary hospital admission.
In this large international study we have confirmed the accuracy of a single test strategy to rule out AMI using a single blood test. Incident MACE including AMI, death and revascularization following re-hospitalization were rare among the group that would have AMI 'ruled out'. However, the incidence of in-hospital revascularization was not negligible. Therefore, the findings from this observational study do suggest that interventional studies are required to further evaluate the efficacy and safety of this strategy when used in practice. In the meantime, clinicians must still exercise judgement prior to discharging patients from the ED. It is possible that the use of validated algorithms such as the Thrombolysis in Myocardial Infarction (TIMI) risk score or the HEART score will assist. Alongside serial sampling for 2-3 hours, the TIMI risk score and HEART score have been shown to identify patients who are at low risk of incident MACE.
14,15
Limitations
It is important to recognize that our study does have some limitations. Our study is observational in nature. It was imperative to report findings from a further large, multi-center observational study
given the important prognostic and medicolegal implications of implementing this early rule out hs-cTnT levels below the LoD and no ECG ischemia, the incidence of MACE in this study was 1.3% after 30 days (3.4% accounting for in-hospital revascularization). Clinicians may feel uncomfortable with this level of risk. The findings of a recent international survey suggest that just under half of emergency physicians would be comfortable to accept a 1% risk that their patient will develop a MACE within 30 days. 16 As a result, the proportion of patients that avoids hospital admission in practice is likely to be lower than the proportion of patients who can have AMI excluded using this strategy. Other clinicians may be less concerned given that the proportion of patients with MACE is largely driven by the high incidence of coronary revascularization in this study. This is arguably a subjective outcome as the revascularization may not always be strictly driven by acute ischemia.
Such patients may also arguably be safely and efficiently treated on an outpatient basis, with the need for revascularization being driven by the persistence of a patient's symptoms. With such considerations, therefore, it remains important to evaluate the impact of this strategy when implemented in practice.
To avoid incorporation bias we adjudicated the diagnosis of AMI based on s-cTnI levels. It is possible that some patients may have developed a late rise of hs-cTnT but did not develop a rise of s-cTnI.
However, in a sensitivity analysis our findings remained unchanged even when the peak hs-cTnT level on serial sampling was used to define AMI.
Finally, it is important to recognise that all research into the diagnostic performance of cardiac troponin is assay-specific. Other cardiac troponin assays may perform differently at thresholds below the conventional 99 th percentile. The performance of a high sensitivity cardiac troponin I in this regard has recently been reported elsewhere. 
Conclusions
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